Clinical Trial Update: Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF [Phase 1]

View source ↗

Summary

Phase 1b safety, tolerability, and pharmacokinetic study of GS-5737 in subjects with cystic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• GS-5737

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED